- RecruitingPHASE3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
This study is testing a new drug called finerenone for people hospitalised with heart failure. We want to see if it's safe and effective for patients whose hearts can still pump blood fairly well, to improve their health and quality of life.
For: Heart Failure · Acute Heart FailureUnited States · Argentina · Australia - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
(22292) Randomized, non-blinded, two-way crossover study to assess bioequivalence between finerenone 2 x 20 mg tablets and 1 x 40 mg tablet in healthy male adult participants
For: Heart failure with left ventricular ejection fraction ≥40%Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22267) A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes
For: Chronic kidney disease associated with type 1 diabetes mellitusItaly · Germany · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21177) A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease
For: Non-diabetic chronic kidney diseaseBulgaria · Denmark · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
For: Chronic Kidney Disease · Type 2 diabetesSpain · Hungary · Poland